Company Overview of McNEIL-PPC, Inc.
McNEIL-PPC, Inc., through its subsidiaries, manufactures pharmaceutical and personal care products. The company was founded in 1879 and is based in Fort Washington, Pennsylvania. McNEIL-PPC, Inc. operates as a subsidiary of Johnson & Johnson.
7050 Camp Hill Road
Fort Washington, PA 19034-2210
Founded in 1879
Key Executives for McNEIL-PPC, Inc.
McNEIL-PPC, Inc. does not have any Key Executives recorded.
McNEIL-PPC, Inc. Key Developments
Reckitt Benckiser Signs Licensing Agreement with McNEIL-PPC
Mar 14 14
Reckitt Benckiser Group PLC signed a licensing agreement with McNEIL-PPC, Inc. for the rights to the K-Y brand, an intimate lubricant. The transaction does not include the employees or fixed assets of McNEIL-PPC. The transaction is expected to close in mid-2014.
Plymouth Superior Court Jury Orders Johnson & Johnson and McNeil Laboratories to Pay a Family $109 Million in Motrin Lawsuit
Feb 14 13
Johnson & Johnson has been told to pay a Massachusetts teenager and her parents $63 million after she suffered a life-threatening drug reaction and lost most of her skin when she took a children's pain reliever nearly a decade ago. A Plymouth Superior Court jury decided Johnson & Johnson and its McNeil Laboratories subsidiary should pay Samantha Reckis and her parents a total of $109 million, including interest. Brad Henry says Samantha was 7 when she was given Motrin brand ibuprofen. She suffered a rare side effect known as toxic epidermal necrolysis and lost 90% of her skin and was blinded.
Supreme Court Not to Review Decision of the Louisiana Court of Appeal Against McNEIL-PPC, Inc
Oct 12 12
The Supreme Court will not review a decision of the Louisiana Court of Appeal affirming a jury verdict in favor of the parents of an infant who died after accidentally being administered Infant's Tylenol instead of the less concentrated Children's Tylenol. The parents filed suit against McNeil-PPC Inc. after they mistakenly administered an overdose of the more-concentrated Infant's Tylenol to their daughter following a nurse's written instruction to give the infant "Tylenol". The complaint against the defendant alleged products liability pursuant to the Louisiana Products Liability Act (LPLA) based on the failure to warn of the risks associated with administering excessive doses of Infant's Tylenol. A jury returned a verdict in the parents' favor. McNeill-PPC appealed. The Louisiana Court of Appeal affirmed the jury's verdict for the parents. The appeals court rejected the defendant's argument that the parents' claims were preempted by the Food, Drug and Cosmetic Act (FDCA) pursuant to the Supreme Court's decision in PLIVA Inc. v. Mensing.
In this case, the defendant is a brand name drug manufacturer that admitted it did not attempt to have all the warnings the parents claim would have prevented the infant's overdose. Therefore, the defendant did not establish that it was impossible to comply with both federal and state law as required to establish preemption under Wyeth v. Levine, 555 U.S. 555 (2009). Wyeth held that state failure to warn claims against a drug manufacturer are not preempted by the FDCA unless the manufacturer establishes that the FDA would not have approved a change to the drug's label and therefore it would be impossible for the manufacturer to comply with both federal and state requirements.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries